Terpene Entourage Effects: A Systematic Review of Synergistic Cannabinoid Interactions
Abstract
Review of 31 studies found mixed evidence for the entourage effect. Myrcene and linalool showed the most consistent synergistic activity with CBD in preclinical models. Clinical evidence remains limited and methodologically heterogeneous.
Study Summary
This systematic review searched PubMed, EMBASE, and Web of Science for studies examining terpene-cannabinoid interactions through February 2026. Of 31 included studies, 24 were preclinical (in vitro or animal) and 7 were clinical. Myrcene demonstrated the most consistent synergistic activity with CBD in anxiety and pain models, potentially through GABA-A receptor modulation. Linalool showed synergistic anxiolytic effects with CBD via 5-HT1A pathways. β-Caryophyllene, as a direct CB2 agonist, showed additive anti-inflammatory effects with CBD. However, clinical studies were highly heterogeneous in design, terpene concentrations, and outcome measures. Three clinical studies found no significant difference between full-spectrum and CBD isolate preparations. The authors conclude that while preclinical evidence supports terpene-cannabinoid synergy, clinical validation is lacking and the entourage effect should not be assumed in clinical practice.
Key Findings
- 1Myrcene and linalool showed most consistent synergistic activity with CBD in preclinical models
- 2β-Caryophyllene (CB2 agonist) demonstrated additive anti-inflammatory effects with CBD
- 33 of 7 clinical studies found no significant difference between full-spectrum and CBD isolate
- 4Clinical evidence for the entourage effect remains limited and methodologically heterogeneous
- 5Terpene concentrations in commercial products often too low to produce pharmacological effects
Clinical Implications
- The entourage effect should not be assumed in clinical practice without patient-specific evidence
- Full-spectrum products are not definitively superior to CBD isolate for most indications
- β-Caryophyllene-rich strains may offer additional anti-inflammatory benefit via CB2
- Standardized terpene profiling is needed for meaningful clinical research
Study Limitations
- Majority of evidence is preclinical — human translation uncertain
- Terpene concentrations in studies often exceed those in commercial products
- No standardized methodology for assessing synergy vs. additivity
- Publication bias likely — negative entourage effect studies may be underreported